Transcriptomics

Dataset Information

0

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses


ABSTRACT: Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective GLS inhibitor, when combined with azacytidine (AZA), in vitro and in vivo, followed by a phase Ib/II study of the combination in patients with advanced MDS. Treatment with telaglenastat/AZA led to an ORR of 70% with CR/mCRs in 53% patients and a median overall survival of 11.6 months. scRNAseq and flow cytometry demonstrated a myeloid differentiation program at the stem cell level in clinical responders. Expression of non-canonical glutamine transporter, SLC38A1, was found to be overexpressed in MDS stem cells; was associated with clinical responses to telaglenastat/AZA and predictive of worse prognosis in a large MDS cohort. These data demonstrate the safety and efficacy of a combined metabolic and epigenetic approach in MDS.

ORGANISM(S): Homo sapiens

PROVIDER: GSE225352 | GEO | 2024/02/12

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-07-23 | GSE154941 | GEO
2018-09-01 | E-MTAB-6648 | biostudies-arrayexpress
2024-06-17 | MTBLS9415 | MetaboLights
2023-05-31 | GSE233764 | GEO
2024-07-21 | GSE272173 | GEO
| S-EPMC9980221 | biostudies-literature
2020-12-25 | GSE155300 | GEO
2018-08-13 | PXD008338 | Pride
2018-08-04 | GSE110198 | GEO
2017-07-20 | GSE76203 | GEO